Figure 3.Relationship between LAPTM4A and prognosis of glioma patients. LGG patients with higher expression levels of LAPTM4A had unfavorable (A) OS, (B) DSS, and (C) PFS. GBMLGG patients with higher expression levels of LAPTM4A had awful (D) OS, (E) DSS, and (F) PFS. GBM patients with higher expression levels of LAPTM4A had undesirable (G) OS, (H) DSS, and (I) PFS.
